Beilu Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 44.1769 million yuan, an increase of 81.10%

Beilu Pharma released its third-quarter report for 2025, with operating revenue of 873 million yuan in the first three quarters, a year-on-year increase of 19.59%. The net profit attributable to the parent company was 44.1769 million yuan, an increase of 81.10%; the net profit excluding non-recurring gains and losses was 33.6758 million yuan, an increase of 33.53%. The basic earnings per share were 0.087 yuan